A new study from Korea University College of Medicine, published in Nature Immunology on June 15, 2026, offers a detailed molecular portrait of how an mRNA-based influenza vaccine may accomplish exactly that. Led by Associate Professor Jiwon Lee of the Department of Convergence Medicine and the Vaccine Innovation Center, and conducted in collaboration with Professor Ali Ellebedy and his group at Washington University in St. Louis, the investigation compared an investigational quadrivalent mRNA influenza vaccine, designated mRNA-1010, against the licensed conventional split-virion vaccine Fluarix in a head-to-head clinical evaluation. The central question was whether the mRNA platform could stimulate stronger and more persistent germinal-center responses than a conventional vaccine, and whether that persistence would translate into a measurably broader antibody repertoire in the blood.

The germinal center is the crucible where vaccine-induced immunity is forged. Within specialized microenvironments of draining lymph nodes, B cells that recognize vaccine antigen undergo rounds of proliferation, somatic hypermutation, and selection. Each cycle introduces random mutations into the genes encoding the B-cell receptor, and only those variants whose mutated receptors bind antigen with higher affinity are permitted to survive and expand. Over weeks, this Darwinian process generates plasma cells that secrete high-affinity antibodies and memory B cells that persist for years. The duration and intensity of germinal-center activity are therefore widely regarded as key determinants of both the breadth and the durability of antibody responses. A vaccine that keeps germinal centers active for longer gives B cells more opportunities to mutate, diversify, and explore antibody solutions that recognize conserved or varied features of the virus.

To test whether mRNA vaccination extends this critical phase, the researchers enrolled 75 healthy adults aged 20 to 50 years and followed them across two influenza seasons. Of these, 38 participants received mRNA-1010 and 37 received Fluarix. Blood samples were collected at multiple time points through 26 weeks after vaccination, allowing the team to track the evolution of circulating antibodies over nearly half a year. Crucially, a subset of participants also underwent ultrasound-guided fine-needle aspiration of draining axillary lymph nodes, an invasive but informative procedure that enabled direct sampling of germinal centers as they formed and matured. This combination of peripheral blood monitoring and lymph-node sampling is rare in human vaccine studies and gave the investigators an unusually complete view of the immune response as it unfolded in real time.

The laboratory analysis was correspondingly comprehensive. The team deployed flow cytometry to characterize immune cell populations, ELISpot assays to quantify antigen-specific antibody-secreting cells, single-cell RNA sequencing and B-cell receptor sequencing to resolve individual B-cell lineages, serum IgG proteomics to catalog circulating antibody clonotypes, and a battery of antibody binding and neutralization assays to test functional activity against antigenically diverse influenza strains. Together, these methods profiled the response at scales ranging from single cells to whole serum, providing a multidimensional dataset that conventional vaccine trials, which typically rely on bulk antibody titers alone, cannot match.

The findings were striking. The mRNA vaccine elicited a substantially more diverse and broader serum antibody repertoire than Fluarix, according to Dr. Lee. Most notably, influenza-specific germinal-center responses persisted for up to 26 weeks in 5 of 13 mRNA-1010 recipients whose draining lymph nodes were sampled, while persistent germinal centers were not detected among any of the Fluarix recipients sampled. Six months of sustained germinal-center activity after a single vaccination is an unusually long window of B-cell evolution, and it suggests that the mRNA platform provides antigen persistence and inflammatory signaling that keep the selection machinery running far longer than a conventional protein-based split-virion preparation.

That prolonged activity left a measurable imprint on the antibody repertoire. The mRNA vaccine increased the diversity of the serum IgG repertoire and promoted the diversification of pre-existing B-cell lineages through somatic hypermutation, meaning that antibodies the immune system had already learned to make against earlier influenza exposures were not merely recalled but actively refined and expanded. These molecular changes were associated with broader antibody binding across antigenically diverse influenza strains and with significantly greater increases in neutralization titers against 11 of 13 A/H1N1 viruses tested. In practical terms, the antibodies generated after mRNA vaccination recognized a wider range of viral variants and neutralized more of them, including strains that differed antigenically from those contained in the vaccine itself. Dr. Lee summarized the distinction succinctly: the mRNA platform does not simply produce more antibodies, it produces a more diversified antibody response, which leads to greater binding and neutralizing breadth.

A key methodological strength of the study was Ig-Seq, a mass-spectrometry-based technology that identifies individual antibody clonotypes circulating in the blood after vaccination. Conventional vaccine studies typically measure bulk binding or neutralization titers, aggregate numbers that reveal how much antibody activity is present but say little about its composition. Ig-Seq resolves the response down to individual antibody clonotypes, revealing which antibody lineages emerged, expanded, and diversified after vaccination. Combined with B-cell receptor sequencing, this molecular-level approach allowed the researchers to trace the genealogical trees of antibody families as they mutated and branched over the six-month observation period, directly linking sustained germinal-center activity in the lymph node to the diversification of antibodies measurable in the serum. The authors identify Ig-Seq as a defining strength of the work because it captures information that bulk serology fundamentally cannot.

The broader implications reach toward the long-sought goal of a more universal influenza vaccine. If mRNA vaccination can sustain germinal-center activity for months rather than weeks, it creates a temporal window in which B cells can accumulate mutations that broaden their recognition of the virus’s antigenic landscape. This mechanism could in principle support protection that carries over between seasons, reducing the need for annual reformulation and re-vaccination. However, the authors are careful to note that further studies are needed to determine whether these broadened responses translate into multi-season protection or permit longer vaccination intervals. The study population consisted of healthy adults aged 20 to 50, and future research must investigate whether the same benefits are maintained in older adults and immunocompromised populations, whose germinal-center function, B-cell repertoire diversity, and overall immune responsiveness differ substantially from those of healthy younger recipients.

What the study establishes, with unusual molecular resolution, is a mechanistic bridge between a vaccine platform and the quality of the immunity it generates. Persistent germinal centers, diversified B-cell lineages, and a broader serum antibody repertoire form a coherent causal chain, and tools such as Ig-Seq now make each link observable in humans. As mRNA technology matures beyond its first applications, findings like these suggest that its most consequential contribution to vaccinology may lie not in speed of development but in the depth and breadth of the immune memory it leaves behind, offering a rational template for influenza vaccines designed to stay ahead of a virus that never stops changing.

Subject of Research: A clinical study comparing mRNA-1010 and Fluarix influenza vaccines in healthy adults, examining germinal-center persistence and antibody repertoire breadth

Article Title: Korea University study uncovers how mRNA vaccination may broaden flu antibody responses

Article References: Korea University study uncovers how mRNA vaccination may broaden flu antibody responses. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: mRNA vaccine, influenza, germinal center, antibody breadth, B cells, somatic hypermutation, Ig-Seq, neutralization, vaccinology, Nature Immunology, Korea University, immune repertoire

The research, published in Veterinary Medicine and Science, focused on five viperid species responsible for a large share of clinically significant snakebites in Iran: Montivipera raddei, Macrovipera lebetina, Echis carinatus, Pseudocerastes persicus, and Gloydius caucasicus. Because victims rarely identify the species that bit them, clinicians typically rely on polyvalent antivenoms raised against panels of local snakes. Whether such broad-spectrum products actually work, however, depends on how much antigenic overlap exists between the venoms of different species, a question the Iranian team set out to answer with a combination of biochemical profiling, immunological assays, and gold-standard in vivo neutralisation tests.

The first step was to quantify how lethal each venom is. In a murine model, the researchers determined median lethal dose values by intravenous injection and probit regression, and the spread was striking. Gloydius caucasicus proved the most toxic, with an LD50 of 0.22 micrograms per gram of body weight, followed closely by Macrovipera lebetina at 0.27, Montivipera raddei at 0.30, and Echis carinatus at 0.56. Pseudocerastes persicus was considerably less potent at 0.87 micrograms per gram. These figures align with earlier reports that Gloydius venom is among the most dangerous in Iran, while also underscoring how toxicity can shift with geography, snake age, diet, and even the route of administration used in testing.

To understand the molecular basis of these differences, the team separated venom proteins by SDS-PAGE electrophoresis under both reducing and non-reducing conditions. All five venoms shared prominent bands at roughly 22, 50, and 130 to 150 kilodaltons, although band intensities varied by species. The approximately 22-kilodalton band, which intensified and shifted to around 14 to 15 kilodaltons after disulphide bonds were broken, is consistent with secreted phospholipase A2 enzymes, small cysteine-rich toxins that drive multiple pharmacological effects in viper envenoming. The 50-kilodalton band, strongest in Pseudocerastes persicus, likely corresponds to snake venom metalloproteinases, the haemorrhage-causing enzymes classified into P-I, P-II, and P-III subclasses. The high-molecular-weight 130 to 150 kilodalton band, which fragmented upon reduction, plausibly represents L-amino acid oxidase homodimers, whose subunits typically run at 55 to 70 kilodaltons.

Reverse-phase high-performance liquid chromatography added a second layer of resolution, generating species-specific chromatographic fingerprints. Gloydius caucasicus showed a dominant mid-range cluster of peaks accounting for nearly 65 percent of detected area, with a single component representing over 30 percent. Echis carinatus displayed the broadest complexity, with seven significant peaks and a mid-range cluster covering 65.6 percent of the area, consistent with proteotranscriptomic studies showing that Echis venoms are richly diverse mixtures of metalloproteinases, serine proteases, C-type lectin-like proteins, and phospholipases A2. Montivipera raddei produced a comparatively simple profile dominated by one late-eluting component, while Macrovipera lebetina resolved into eight main peaks. Pseudocerastes persicus stood apart with a distinctive early-eluting fraction absent from all other venoms, a feature attributed to abundant phospholipases A2, L-amino acid oxidases, and unique peptide components reported in prior proteomic work.

With the venoms characterised, the researchers immunised New Zealand White rabbits, dividing them into monovalent groups receiving single venoms and a polyvalent group receiving an equal-volume mixture of all five. Indirect ELISA then measured how each antivenom bound homologous and heterologous venoms. The results revealed a remarkable spectrum of cross-reactivity. Antivenom raised against Montivipera raddei was the broadest recognizer, binding Pseudocerastes persicus at 92 percent, Echis carinatus at 91 percent, Macrovipera lebetina at 95 percent, and Gloydius caucasicus at 80 percent of homologous levels. Pseudocerastes persicus antivenom also cross-reacted strongly with most relatives, but only weakly with Gloydius caucasicus at 44 percent. At the other extreme, Gloydius caucasicus antivenom showed the lowest heterologous binding of all, while the polyvalent preparation bound every venom at 95 percent or higher, confirming that combining five immunogens did not compromise the antibody response.

Crucially, binding did not always predict neutralisation, a well-known limitation of ELISA, which cannot distinguish neutralising antibodies from those that merely recognise epitopes. In vivo assays challenging mice with five lethal doses of venom pre-incubated with antivenom told a more nuanced story. Each monovalent antivenom was most potent against its own venom, as expected, but meaningful cross-neutralisation emerged in several pairings. Macrovipera lebetina and Montivipera raddei antivenoms neutralised Pseudocerastes persicus venom at 1.17 and 1.07 milligrams of venom per millilitre of antivenom respectively, while Pseudocerastes antivenom neutralised Montivipera raddei at 0.49 and Echis carinatus at 0.66 milligrams per millilitre. Gloydius caucasicus antivenom, in sharp contrast, neutralised only its homologous venom and showed little or no activity against any heterologous venom tested. The polyvalent formulation neutralised all five venoms, performing best against Pseudocerastes persicus and Echis carinatus and weakest against Gloydius caucasicus.

The authors interpret these patterns through the lens of shared and divergent toxin families. Broad cross-reactivity among Montivipera, Macrovipera, and Pseudocerastes likely reflects conserved metalloproteinases and phospholipases A2, the dominant immunogens of Old World viper venoms. The poor performance of Gloydius caucasicus antivenom mirrors findings from other Gloydius species, whose distinct venom compositions, possibly including unique haemorrhagic metalloproteinases, demand species-specific antibodies. Comparable studies elsewhere reinforce the picture: Thai monovalent antivenoms show variable cross-neutralisation across Asian vipers, Pakistani Viper Antivenom cross-neutralises saw-scaled and Russell’s viper subspecies across the Indian subcontinent, and the polyvalent Inoserp Europe covers several Vipera, Montivipera, and Macrovipera species, consistent with conserved toxin architecture within the subfamily Viperinae.

The practical implications are direct. Venoms that generate both strong cross-reactivity and cross-neutralisation, such as those of Montivipera raddei and Macrovipera lebetina, are strong candidates for inclusion in immunisation mixtures aimed at paraspecific protection. Venoms with narrow cross-neutralisation, above all Gloydius caucasicus, must be explicitly represented in any formulation intended to cover the full Iranian viper spectrum. The findings also echo clinical experience: a study of 44 viper-envenomed patients treated with Iranian polyvalent antivenom documented reduced envenoming severity and normalised coagulation parameters within 12 hours, supporting the therapeutic value of polyspecific products when species identification is uncertain.

The researchers caution that their SDS-PAGE and RP-HPLC data are comparative fingerprints rather than definitive proteomic assignments, and that converting chromatographic peaks into precise toxin identities requires LC-MS/MS-based venomics and antivenomics. They also note that immunological profiles depend heavily on the host animal used for antibody production, so results from rabbits cannot be extrapolated directly to horse-derived commercial antivenoms. Even so, by integrating lethality, protein profiling, binding, and neutralisation into a single comparative framework, the study delivers exactly the kind of evidence base needed to rationally reformulate antivenoms for a region where five vipers, each with its own toxic signature, share the same landscapes and the same emergency rooms.

Subject of Research: Immunological cross-reactivity and neutralizing efficacy of antivenom against five medically important Iranian viper venoms

Article Title: Immunological Cross‐Reactivity and Neutralizing Efficacy of Antivenom Against Five Medically Important Iranian Viper Venoms

Article References: Khamehchian, S., Tahoori, F., Rabie, H., Nasrabadi, N. N., & Tebianian, M. (2026). Immunological Cross‐Reactivity and Neutralizing Efficacy of Antivenom Against Five Medically Important Iranian Viper Venoms. Veterinary Medicine and Science, 12(5), Article e71193. https://doi.org/10.1002/vms3.71193

Image Credits: AI Generated

DOI: 10.1002/vms3.71193

Keywords: snakebite, antivenom, Iranian vipers, venom cross-reactivity, neutralization, venomics, ELISA, LD50, phospholipase A2, metalloproteinases, polyvalent antivenom, Gloydius caucasicus